Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Parrondo

Showing results (181-190 of 234) with videos related to

Pageof 24
Sort By:
Leukemia|March 21, 2025
Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysisHira Mian, Thomas G Martin, Gregory R Pond, et al.
Blood Cancer Journal|June 1, 2022
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myelomaRicardo D Parrondo, Zaid Abdel Rahman, Michael G Heckman, et al.
Gastroenterologia Y Hepatologia|July 1, 2024
Artificial intelligence-assisted identification and retrieval of chronic hepatitis C patients lost to follow-up in the health area of Pontevedra and O Salnés (Spain)Pablo Parada Vázquez, Santiago Pérez-Cachafeiro, Belén Castiñeira Domínguez, et al.
Environmental Research|September 12, 2022
Effectiveness of COVID-19 vaccine booster in the general population and in subjects with comorbidities. A population-based study in SpainNarmeen Mallah, Jacobo Pardo-Seco, Luis-Ricardo López-Pérez, et al.
British Journal of Haematology|July 16, 2022
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemiaPaul J Hampel, Kari G Rabe, Timothy G Call, et al.
Anti-Cancer Drugs|April 17, 2023
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myelomaMuhamad Alhaj Moustafa, Ricardo Parrondo, Mays F Abdulazeez, et al.
Cancers|January 21, 2023
AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple MyelomaSikander Ailawadhi, Ricardo D Parrondo, Navnita Dutta, et al.
JCO Oncology Practice|December 20, 2024
Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing AdministrationTyler B Sandahl, Scott A Soefje, Rafael Fonseca, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|October 25, 2023
COVID-19 vaccine effectiveness in children by age groups. A population-based study in Galicia, SpainNarmeen Mallah, Jacobo Pardo-Seco, Sonia Ares-Gómez, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 12, 2026
Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple MyelomaBenjamin Hebraud, Charis Charalampous, Ricardo Parrondo, et al.
Pageof 24

Showing results (181-190 of 234) with videos related to

Sort By:
Pageof 24
Leukemia|March 21, 2025
Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysisHira Mian, Thomas G Martin, Gregory R Pond, et al.
Blood Cancer Journal|June 1, 2022
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myelomaRicardo D Parrondo, Zaid Abdel Rahman, Michael G Heckman, et al.
Gastroenterologia Y Hepatologia|July 1, 2024
Artificial intelligence-assisted identification and retrieval of chronic hepatitis C patients lost to follow-up in the health area of Pontevedra and O Salnés (Spain)Pablo Parada Vázquez, Santiago Pérez-Cachafeiro, Belén Castiñeira Domínguez, et al.
Environmental Research|September 12, 2022
Effectiveness of COVID-19 vaccine booster in the general population and in subjects with comorbidities. A population-based study in SpainNarmeen Mallah, Jacobo Pardo-Seco, Luis-Ricardo López-Pérez, et al.
British Journal of Haematology|July 16, 2022
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemiaPaul J Hampel, Kari G Rabe, Timothy G Call, et al.
Anti-Cancer Drugs|April 17, 2023
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myelomaMuhamad Alhaj Moustafa, Ricardo Parrondo, Mays F Abdulazeez, et al.
Cancers|January 21, 2023
AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple MyelomaSikander Ailawadhi, Ricardo D Parrondo, Navnita Dutta, et al.
JCO Oncology Practice|December 20, 2024
Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing AdministrationTyler B Sandahl, Scott A Soefje, Rafael Fonseca, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|October 25, 2023
COVID-19 vaccine effectiveness in children by age groups. A population-based study in Galicia, SpainNarmeen Mallah, Jacobo Pardo-Seco, Sonia Ares-Gómez, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 12, 2026
Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple MyelomaBenjamin Hebraud, Charis Charalampous, Ricardo Parrondo, et al.
Pageof 24